Key points are not available for this paper at this time.
Keeps pharmacists abreast of expanding cardiovascular pharmacotherapy data; leaves open the need for targeted trials before practice changes.
This continuing feature will update readers on recent developments in cardiovascular pharmacotherapy. Cardiovascular disease remains the number one killer in the US, and more clinical outcome trials have been conducted in cardiology than in any other field of medicine. Given this rapidly expanding knowledge base, pharmacists can have a significant impact on the prevention and treatment of cardiovascular disease—if they keep current with developments in drug therapy.
No takes yet. Share an insight, caveat, or question.
Patricia Howard (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: